Zhejiang Jianfeng Group Co., Ltd. Third Quarter Report 2018 Text
Release time:
2020-07-07
公司代码:600668 公司简称:尖峰集团
浙江尖峰集团股份有限公司
2018年第三季度报告正文
一、 重要提示
1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
1.2 公司全体董事出席董事会审议季度报告。
1.3 公司负责人蒋晓萌、主管会计工作负责人兰小龙及会计机构负责人(会计主管人员)吴德富保证季度报告中财务报表的真实、准确、完整。
1.4 本公司第三季度报告未经审计。
二、 公司主要财务数据和股东变化
2.1 主要财务数据
单位:元 币种:人民币
|
|
本报告期末 |
上年度末 |
本报告期末比上年度末增减(%) |
|
总资产 |
4,787,531,214.62 |
4,175,730,846.73 |
14.65 |
|
归属于上市公司股东的净资产 |
3,091,664,703.46 |
2,627,318,888.65 |
17.67
|
|
|
年初至报告期末 (1-9月) |
上年初至上年报告期末 (1-9月) |
比上年同期增减(%) |
|
经营活动产生的现金流量净额 |
375,343,924.71 |
194,680,761.60 |
92.80 |
|
|
年初至报告期末 (1-9月) |
上年初至上年报告期末 (1-9月) |
比上年同期增减 (%) |
|
营业收入 |
2,308,365,252.61 |
1,966,202,048.98 |
17.40 |
|
归属于上市公司股东的净利润 |
488,183,289.95 |
291,408,643.10 |
67.53 |
|
归属于上市公司股东的扣除非经常性损益的净利润 |
473,663,318.81 |
277,934,952.23 |
70.42 |
|
加权平均净资产收益率(%) |
17.05 |
11.74 |
增加5.31个百分点 |
|
基本每股收益(元/股) |
1.4188 |
0.8469 |
67.53 |
|
稀释每股收益(元/股) |
1.4188 |
0.8469 |
67.53 |
非经常性损益项目和金额
单位:元 币种:人民币
|
项目 |
本期金额 (7-9月) |
年初至报告期末金额(1-9月) |
说明 |
|
非流动资产处置损益 |
17,071.47 |
25,797.10 |
|
|
越权审批,或无正式批准文件,或偶发性的税收返还、减免 |
1,344,590.41 |
2,037,104.39 |
|
|
计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国家政策规定、按照一定标准定额或定量持续享受的政府补助除外 |
6,010,443.10 |
15,471,116.32 |
|
|
委托他人投资或管理资产的损益 |
169,552.87 |
1,535,544.14 |
|
|
除上述各项之外的其他营业外收入和支出 |
-24,177.80 |
-680,195.47 |
|
|
少数股东权益影响额(税后) |
-346,385.71 |
-472,835.16 |
|
|
所得税影响额 |
-1,511,067.33 |
-3,396,560.18 |
|
|
合计 |
5,660,027.01 |
14,519,971.14 |
|
2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持股情况表
单位:股
|
股东总数(户) |
29,258 |
||||||
|
前十名股东持股情况 |
|||||||
|
股东名称 (全称) |
期末持股数量 |
比例(%) |
持有有限售条件股份数量 |
质押或冻结情况 |
股东性质 |
||
|
股份状态 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
16.15 |
0 |
无 |
0 |
国有法人 |
|
|
国通信托有限责任公司-国通信托·惠钰1号单一资金信托 |
9,234,900 |
2.68 |
0 |
无 |
0 |
未知 |
|
|
国民信托有限公司-国民信托·华富3号证券投资单一资金信托 |
6,922,000 |
2.01 |
0 |
无 |
0 |
未知 |
|
|
香港中央结算有限公司 |
4,510,078 |
1.31 |
0 |
无 |
0 |
未知 |
|
|
浙江康恩贝制药股份有限公司 |
3,742,992 |
1.09 |
0 |
无 |
0 |
境内非国有法人 |
|
|
何文康 |
3,439,100 |
1.00 |
0 |
无 |
0 |
境内自然人 |
|
|
王晓红 |
3,121,943 |
0.91 |
0 |
无 |
0 |
境内自然人 |
|
|
骆惠娟 |
2,976,200 |
0.86 |
0 |
无 |
0 |
境内自然人 |
|
|
钟以隆 |
2,650,000 |
0.77 |
0 |
无 |
0 |
境内自然人 |
|
|
徐新华 |
2,544,661 |
0.74 |
0 |
无 |
0 |
境内自然人 |
|
|
前十名无限售条件股东持股情况 |
|||||||
|
股东名称 |
持有无限售条件流通股的数量 |
股份种类及数量 |
|||||
|
种类 |
数量 |
||||||
|
金华市通济国有资产投资有限公司 |
55,564,103 |
人民币普通股 |
55,564,103 |
||||
|
国通信托有限责任公司-国通信托·惠钰1号单一资金信托 |
9,234,900 |
人民币普通股 |
9,234,900 |
||||
|
国民信托有限公司-国民信托·华富3号证券投资单一资金信托 |
6,922,000 |
人民币普通股 |
6,922,000 |
||||
|
香港中央结算有限公司 |
4,510,078 |
人民币普通股 |
4,510,078 |
||||
|
浙江康恩贝制药股份有限公司 |
3,742,992 |
人民币普通股 |
3,742,992 |
||||
|
何文康 |
3,439,100 |
人民币普通股 |
3,439,100 |
||||
|
王晓红 |
3,121,943 |
人民币普通股 |
3,121,943 |
||||
|
骆惠娟 |
2,976,200 |
人民币普通股 |
2,976,200 |
||||
|
钟以隆 |
2,650,000 |
人民币普通股 |
2,650,000 |
||||
|
徐新华 |
2,544,661 |
人民币普通股 |
2,544,661 |
||||
|
上述股东关联关系或一致行动的说明 |
本公司第一大股东通济国投与其他上述第2名至第10名无限售条件股东之间不存在关联关系。公司未知其他9名股东之间是否存在关联关系,也未知是否属于《上市公司收购管理办法》规定的一致行动人。 |
||||||
|
表决权恢复的优先股股东及持股数量的说明 |
不适用 |
||||||
2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股东持股情况表
三、 重要事项
3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
|
资产负债表项目 |
期末数(万元) |
期初数(万元) |
变动幅度 |
变动原因 |
|
预付帐款 |
10,245.02 |
4,610.82 |
122.20% |
主要系本报告期子公司预付货款增加所致。 |
|
其他应收款 |
2,095.55 |
1,308.75 |
60.12% |
主要系报告期公司的投资单位已宣告但尚未发放的现金股利增加所致。 |
|
其他流动资产 |
14,482.18 |
1,328.92 |
989.77% |
主要系报告期公司购买的短期银行结构性存款理财产品所致。 |
|
投资性房地产 |
7,964.52 |
2,145.61 |
271.20% |
主要系报告期子公司尖峰国贸在建电商物流园项目部分结转增加所致。 |
|
在建工程 |
2,542.40 |
4,557.67 |
-44.22% |
主要系报告期子公司在建工程项目部分结转相应资产所致。 |
|
商誉 |
7,549.90 |
1,629.86 |
363.22% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
长期待摊费用 |
244.21 |
175.03 |
39.52% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
短期借款 |
14,900.00 |
8,900.00 |
67.42% |
主要系报告期公司及子公司增加银行借款所致。 |
|
应付职工薪酬 |
1,267.86 |
3,627.55 |
-65.05% |
主要系报告期公司及子公司发放上年末计提的年终奖所致。 |
|
其他应付款 |
28,672.64 |
17,432.86 |
64.47% |
主要系报告期子公司计提的市场推广费和其他支出增加及子公司股东会决议宣告但尚未发放的2017年度现金股利增加所致。 |
|
一年内到期的非流动负债 |
0.00 |
27,631.69 |
-100.00% |
主要系报告期公司按期兑付到期的公司债券所致。 |
|
长期借款 |
13,200.00 |
0.00 |
100.00% |
主要系报告期公司新增的长期银行借款及新增合并企业众望制药所致。 |
|
少数股东权益 |
27,469.76 |
19,695.14 |
39.47% |
主要系报告期公司新增合并企业上海北卡所致。 |
|
利润表项目 |
本期数(万元) |
上年同期数(万元) |
变动幅度 |
变动原因 |
|
税金及附加 |
2,156.55 |
1,414.54 |
52.46% |
主要系报告期子公司营业收入增加相应的税金及附加增加所致。 |
|
销售费用 |
34,510.47 |
19,767.16 |
74.58% |
主要系报告期子公司尖峰药业销售收入的增长和销售模式的调整,公司销售费用中相应增加了市场推广费和其他支出。 |
|
投资收益 |
17,306.51 |
10,365.66 |
66.96% |
主要系报告期公司联营投资单位南方尖峰水泥有限公司利润大幅增长,公司权益法核算计入投资收益相应增加所致。 |
|
所得税费用 |
11,927.05 |
7,392.18 |
61.35% |
主要系本报告期子公司实现的利润总额增加相应的所得税费用增加所致。 |
|
现金流量表项目 |
|
|
|
|
|
经营活动产生的现金流量净额 |
37,534.39 |
19,468.08 |
92.80% |
主要系报告期公司销售收入增长及营业利润大幅增加所致。 |
|
投资活动产生的现金流量净额 |
-24,857.50 |
-21,162.20 |
|
|
|
筹资活动产生的现金流量净额 |
-19,354.57 |
-5,320.98 |
|
主要系报告期公司到期兑付了公司债券本金及利息所致。 |
3.2 重要事项进展情况及其影响和解决方案的分析说明
1.2017年8月3日,本公司九届14次董事会通过了《关于山亚南方股权重组的关联交易的议案》。
本公司控股子公司尖峰水泥持有南方尖峰35%股权,金华南方水泥有限公司(以下简称“金华南方”)持有南方尖峰65%股权;南方尖峰持有杭州山亚南方水泥有限公司(以下简称“山亚南方”)的100%股权。为了压减企业层级、提高运营效率,拟对山亚南方进行股权重组,南方尖峰将所持有的山亚南方100%股权上移,分别转让给尖峰水泥与金华南方两个股东,尖峰水泥与金华南方按所占南方尖峰的股权比例受让山亚南方股权,其中:尖峰水泥拟出资62,099,765元受让山亚南方的35%股权;金华南方拟出资115,328,135元受让山亚南方的65%股权。股权重组完成后,山亚南方的股权层级将上移,重组前后本公司所持该股权的整体权益没有变化。详见2017年8月3日本公司在上海证券交易所网站披露的临2017-019《关于山亚南方股权重组的关联交易公告》。截止报告期末,因支付股权转让款的前提条件尚未达到,该股权重组事项尚未实施。该事项不会影响公司所持的该股权的整体权益。
2.2018年8月3日,公司十届5次董事会通过了《关于子公司尖峰药业对上海北卡增资的议案》本公司控股子公司尖峰药业出资人民币5000万元,自然人吴江出资人民币1000万元,对上海北卡进行增资,其他股东放弃参与本次增资。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-025《关于子公司尖峰药业对上海北卡增资的公告》。截止报告期末,本次增资事宜已经完成,上海北卡已经完成了工商变更登记手续。上海北卡注册资本由原来的1755.55万元增加至2275.93万元,其中尖峰药业占61.48%。
3. 2018年8月3日,公司十届5次董事会通过了《关于子公司上海北卡收购安徽众望的议案》。本公司控股子公司上海北卡医药技术有限公司出资2062万元,收购安徽众望制药有限公司的全部100%股权,收购完成后安徽众望将成为上海北卡的全资子公司。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-023《关于子公司上海北卡收购安徽众望的公告》。截止报告期末,该股权收购事宜已经完成,安徽众望已经完成工商变更登记手续,成为上海北卡的全资子公司。
4. 2018年8月3日,公司十届5次董事会通过了《关于尖峰药业金西生产基地年产20亿片固体制剂项目的议案》,同意尖峰药业投资建设金西生产基地年产20亿片固体制剂项目。上述事项详见2018年8月4日本公司披露于上海证券交易所网站(http//:www.sse.com.cn/)的临2018-022《十届5次董事会决议公告》和临2018-024《关于尖峰药业金西生产基地年产20亿片固体制剂项目的公告》。截止报告期末,金西生产基地年产20亿片固体制剂项目的土地指标已经落实,主体工艺设备选型基本完成,工艺设计正在进行中。
5.2017年2月29日,公司九届十次董事会审议通过的《关于子公司对外投资的议案》,本公司控股子公司浙江尖峰药业有限公司拟以增资和股权转让的方式,分期对北京慧宝源生物技术股份有限公司进行投资,其中:第一期出资8,000万元,以每股4元的价格对慧宝源生物增资2,000万股;第二期出资8,600万元,以每股4.30元的价格对慧宝源生物增资2,000万股,另出资3,010万元以每股4.30元的价格受让桂林商源出让的慧宝源生物股权700万股;第三、第四期各对慧宝源生物增资1,400万股,增资价格以届时各方共同认可并聘请的具有证券从业资格的资产评估机构进行评估,以评估结果为基础协商确定。截止报告期末,浙江尖峰药业有限公司已完成了第一期出资,占北京慧宝源生物技术股份有限公司20%的股权。
3.3 报告期内超期未履行完毕的承诺事项
3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大变动的警示及原因说明
|
公司名称 |
浙江尖峰集团股份有限公司 |
|
法定代表人 |
蒋晓萌 |
|
日期 |
2018年10月30日 |
- 发布时间: 2018-10-31
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31